

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
**WO 2005/014529 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 233/26**,  
C07D 209/40, 215/38, A61K 31/167, 31/47, 31/404, A61P  
29/00

(21) International Application Number:  
PCT/SE2004/001154

(22) International Filing Date: 28 July 2004 (28.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0302192-0 8 August 2003 (08.08.2003) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLADINGBOEL, David** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **FORD, Rhonan** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **WILLIS, Paul** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

#### Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS.



(57) Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or solvate or pro-drug thereof, wherein A, B, X, n and m have the meanings as defined in the specification. Processes for their preparation; pharmaceutical compositions containing them; and their use in therapy are also described.

WO 2005/014529 A1

2-adamantyl derivatives as P2X<sub>7</sub> receptor antagonists.


The present invention relates to certain adamantane derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. In particular, the present invention relates to 2-adamantyl derivatives effective as P2X<sub>7</sub> receptor antagonists.

The P2X<sub>7</sub> receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation of the P2X<sub>7</sub> receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 $\beta$  (IL-1 $\beta$ ) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and proliferation (T cells), apoptosis and L-selectin shedding (lymphocytes). P2X<sub>7</sub> receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells), hepatocytes and mesangial cells.

It would be desirable to make compounds effective as P2X<sub>7</sub> receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X<sub>7</sub> receptor may play a role.

1-Adamantyl derivatives having antagonist activity at the P2X<sub>7</sub> receptor are known in the art and are described, for example, in WO 99/29660, WO 00/61569 and WO 01/94338.

The present invention provides a compound of formula (I)




or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

A represents a phenyl, pyridyl, indolyl, indazolyl, purinyl, pyrimidinyl, thiophenyl, benzothiazolyl, quinolinyl or isoquinolinyl group, each of which may be optionally

substituted by one or more substituents, which may be the same or different, selected from

- 5 halogen, amino, nitro, cyano, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by at least one substituent selected from hydroxyl or halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, or a group of formula




where Y represents an oxygen or sulphur atom or a group -N(R<sup>3</sup>)-;

p is 0 or 1;

- 10 R<sup>1</sup> represents a bond or a C<sub>1</sub>-C<sub>6</sub> alkyl group which may be optionally substituted by at least one substituent selected from hydroxyl, halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkoxy, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, phenyl (optionally substituted by at least one substituent selected from halogen, hydroxyl and C<sub>1</sub>-C<sub>6</sub> alkylsulphonylamino), benzyl, indolyl (optionally substituted by at least one substituent
- 15 selected from C<sub>1</sub>-C<sub>6</sub> alkoxy), oxopyrrolidinyl, phenoxy, benzodioxolyl, phenoxyphenyl, piperidinyl and benzyloxy;

R<sup>2</sup> represents hydrogen, hydroxyl, -NR<sup>4</sup>R<sup>5</sup>, except that when R<sup>1</sup> represents a bond, then R<sup>2</sup> represents a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being

20 optionally substituted by at least one substituent selected from hydroxyl, amino (-NH<sub>2</sub>), C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkylamino, -NH(CH<sub>2</sub>)<sub>2</sub>OH, -NH(CH<sub>2</sub>)<sub>3</sub>OH, NH(CH<sub>2</sub>)<sub>4</sub>OH,



- R<sup>3</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group which may be optionally substituted
- 25 by at least one substituent selected from hydroxyl, halogen and C<sub>1</sub>-C<sub>6</sub> alkoxy;
- R<sup>4</sup> and R<sup>5</sup> each independently represent hydrogen, pyrrolidinyl, piperidinyl, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, C<sub>2</sub>-C<sub>7</sub> alkenyl, or C<sub>1</sub>-C<sub>7</sub> alkyl optionally substituted with at least one substituent selected from carboxyl, hydroxyl, amino (-NH<sub>2</sub>), C<sub>1</sub>-C<sub>6</sub> alkylamino, di-C<sub>1</sub>-C<sub>6</sub>

- alkylamino,  $-\text{NH}(\text{CH}_2)_2\text{OH}$ ,  $\text{C}_1\text{-C}_6$  alkoxy,  $\text{C}_1\text{-C}_6$  alkylthio,  $\text{C}_1\text{-C}_6$  alkoxycarbonyl, and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by at least one substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  hydroxyalkyl,  $-\text{NR}^6\text{R}^7$ ,  $-(\text{CH}_2)_r\text{NR}^8\text{R}^9$  and  $-\text{CONR}^{10}\text{R}^{11}$ ,  
5 or  $\text{R}^4$  and  $\text{R}^5$  may together with the nitrogen atom to which they are attached form a saturated 4- to 8-membered heterocyclic ring which may comprise a second ring heteroatom selected from nitrogen and oxygen, the ring being optionally substituted by at least one  
10 substituent selected from hydroxyl, halogen,  $\text{C}_1\text{-C}_6$  alkyl, and  $\text{C}_1\text{-C}_6$  hydroxyalkyl  
 $r$  is 1, 2, 3, 4, 5 or 6;  
 $\text{R}^6$  and  $\text{R}^7$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^6$  and  $\text{R}^7$  together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring;  
15  $\text{R}^8$  and  $\text{R}^9$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^8$  and  $\text{R}^9$  together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring; and  
 $\text{R}^{10}$  and  $\text{R}^{11}$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^{10}$  and  $\text{R}^{11}$  together with the nitrogen  
20 atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring;  
 $\text{B}$  represents  $\text{C}(\text{O})\text{NH}$  or  $\text{NHC}(\text{O})$ ;  
 $n$  is 1, 2, 3, 4, 5 or 6;  
each  $\text{X}$  is independently selected from halogen or  $\text{C}_1\text{-C}_6$  alkoxy; and  
 $m$  is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9;  
25 with the proviso that when  $\text{B}$  represents  $\text{C}(\text{O})\text{NH}$ ,  $n$  is 1 and  $m$  is 0, then  $\text{A}$  is not an unsubstituted phenyl group.

As used herein, the term "halogen" includes fluorine, chlorine, bromine and iodine, and in particular is fluorine or chlorine.

Unless otherwise indicated, the term 'alkyl', when used alone or in combination, refers to a straight or branched chain alkyl moiety. A C<sub>1</sub>-C<sub>6</sub> alkyl group has from one to six carbon atoms, including methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl and the like. 'C<sub>1</sub>-C<sub>5</sub> alkyl' and 'C<sub>1</sub>-C<sub>7</sub> alkyl' will be understood accordingly to mean a  
5 straight or branched chain alkyl moiety having from one to five or one to seven carbon atoms respectively.

The term 'cycloalkyl' refers to a saturated alicyclic moiety having from three to eight carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and  
10 cyclohexyl.

The expression "heterocyclic" includes saturated and unsaturated rings having from 3 up to 10 atoms, at least one of which is a heteroatom selected from oxygen, sulphur or nitrogen. The rings may be mono- or bicyclic and may have alicyclic or aromatic properties. Bicyclic  
15 rings may be fully or partially aromatic in character. An unsaturated ring system may be fully or partially unsaturated. Nitrogen heteroatoms will be substituted as necessary, and may also be in the form of *N*-oxides. Sulphur atoms may be in the form of S, S(O) or S(O<sub>2</sub>). Where it is intended that the heterocyclic ring has a maximum number of ring atoms that is less than ten, this is specified. Where it is intended that a ring heteroatom is one of N, S or  
20 O in particular, or that the heterocyclic ring comprises one or more ring heteroatoms in specific combination, this is indicated.

'Optionally substituted' is used herein to indicate optional substitution by the group or groups specified at any suitable available position.

25

A "hydroxyalkyl" substituent may contain one or more hydroxyl groups but preferably contains one hydroxyl group.

It will be understood that where B represents C(O)NH the compounds of formula (I) comprise a group A-C(O)NH-(CH<sub>2</sub>)<sub>n</sub>-; and when B represents NHC(O) the compounds of formula (I) comprise a group A-NHC(O)-(CH<sub>2</sub>)<sub>n</sub>-.

- 5 In an embodiment of the invention, A represents a phenyl, pyridyl, indolyl or quinolyl group which is optionally substituted as defined above. Preferably, A represents a phenyl, pyridyl or quinolyl group which is optionally substituted as defined above.

- Preferred substituents for the ring A include halogen (for example fluorine or chlorine),  
 10 amino, nitro, cyano, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl (for example, methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by at least one substituent selected from hydroxyl and halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy (for example methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy), or a group of formula -[Y]<sub>p</sub>-R<sup>1</sup>-R<sup>2</sup> (II).

- 15 Where Y represents -N(R<sup>3</sup>)-, R<sup>3</sup> is a hydrogen atom or a C<sub>1</sub>-C<sub>5</sub> alkyl group which may optionally substituted by at least one substituent (for example, one, two or three substituents independently) selected from hydroxyl, halogen (for example, fluorine, chlorine, bromine or iodine) and C<sub>1</sub>-C<sub>6</sub> alkoxy (for example, methoxy or ethoxy).

- 20 Preferably, R<sup>3</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>5</sub> alkyl group which may be optionally substituted by at least one hydroxyl group.


- R<sup>1</sup> represents a bond or a C<sub>1</sub>-C<sub>6</sub>, preferably C<sub>1</sub>-C<sub>4</sub> alkyl group, substituted by at least one substituent (for example one, two or three substituents independently) selected from  
 25 hydroxyl, halogen (for example, fluorine or chlorine), C<sub>1</sub>-C<sub>6</sub> alkoxy (for example, methoxy or ethoxy), C<sub>1</sub>-C<sub>6</sub> alkylthio (for example, methyl- or ethyl-thio), C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl (such as hydroxymethyl), C<sub>1</sub>-C<sub>6</sub> hydroxyalkyloxy, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl (for example, methoxycarbonyl), C<sub>3</sub>-C<sub>8</sub> cycloalkyl (for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), phenyl (optionally substituted by at least one substituent selected from

halogen, hydroxyl and C<sub>1</sub>-C<sub>6</sub> alkylsulphonylamino, such as methylsulphonylamino), benzyl, indolyl (optionally substituted by at least one substituent selected from C<sub>1</sub>-C<sub>6</sub> alkoxy such as methoxy), oxopyrrolidinyl, phenoxy, benzodioxolyl, phenoxyphenyl, piperidinyl and benzyloxy.

5

In an embodiment of the invention, R<sup>1</sup> represents a bond or a C<sub>1</sub>-C<sub>4</sub> alkyl group which may be optionally substituted by one, two or three substituents independently selected from hydroxyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, methylthio, C<sub>1</sub>-C<sub>2</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>2</sub> hydroxyalkyloxy, methoxycarbonyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, phenyl (optionally substituted by at least one  
 10 substituent selected from halogen, hydroxyl and methylsulphonylamino), benzyl, indolyl (optionally substituted by at least one methoxy), oxopyrrolidinyl, phenoxy, benzodioxolyl, phenoxyphenyl, piperidinyl and benzyloxy.

R<sup>2</sup> represents hydrogen, hydroxyl, or a group -NR<sup>4</sup>R<sup>5</sup> except that when R<sup>1</sup> represents a  
 15 bond, then R<sup>2</sup> represents a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom (for example, one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by at least one substituent (for example, one, two, three or four substituents independently) selected from hydroxyl, amino (-NH<sub>2</sub>), C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>  
 20 alkylamino, -NH(CH<sub>2</sub>)<sub>2</sub>OH, -NH(CH<sub>2</sub>)<sub>3</sub>OH, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, benzyl, and



When R<sup>2</sup> represents a saturated or unsaturated 3 to 10 membered ring system, this ring system is preferably cyclobutyl, cyclohexyl, bicyclo[2.2.1]hept-2-yl, 2,3-dihydro-1H-indenyl, pyrrolidinyl, piperidinyl or piperazinyl.  
 25

In an embodiment of the invention,  $R^4$  and  $R^5$  each independently represent hydrogen, pyrrolidinyl,  $C_1$ - $C_2$  alkylcarbonyl,  $C_5$ - $C_7$  alkenyl, or  $C_1$ - $C_7$  alkyl optionally substituted with one or two substituents independently selected from carboxyl, hydroxyl, amino,  $C_1$ - $C_2$  alkylamino, di- $C_1$ - $C_2$  alkylamino,  $-NH(CH_2)_2OH$ ,  $C_1$ - $C_2$  alkoxy,  $C_1$ - $C_2$  alkylthio,  $C_1$ - $C_2$  alkoxy, and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by at least one substituent (e.g. one, two, three or four substituents independently) selected from fluorine, hydroxyl, oxo, carboxyl, cyano,  $C_1$ - $C_2$  alkyl,  $C_1$ - $C_2$  hydroxyalkyl,  $-NR^6R^7$ ,  $-(CH_2)_rNR^8R^9$  and  $-CONR^{10}R^{11}$ .

The saturated or unsaturated 3- to 10-membered ring system referred to in the preceding paragraph is preferably selected from cyclopropyl, cyclohexenyl, phenyl, thienyl, pyridinyl, furyl, bicyclo[2.2.1]hept-5-en-2-yl, 3,4-dihydro-2H-pyran, thiazolyl, pyrrolyl, pyrazolyl, imidazolyl and thiadiazolyl.

In another embodiment of the invention, where  $R^4$  and  $R^5$  together with the nitrogen atom to which they are attached form a saturated six-membered heterocyclic ring, this ring is optionally substituted by at least one substituent (for example, one, two, three or four substituents independently) selected from hydroxyl, halogen (for example, fluorine, chlorine, bromine or iodine),  $C_1$ - $C_6$  alkyl (such as methyl or ethyl), and  $C_1$ - $C_6$  hydroxyalkyl (for example, hydroxymethyl or hydroxyethyl). Preferably, the heterocyclic ring is a piperidinyl, piperazinyl or morpholinyl ring.

$R^6$  and  $R^7$  each independently represent a hydrogen atom, a  $C_1$ - $C_6$  alkyl group such as methyl or ethyl, a  $C_2$ - $C_6$  hydroxyalkyl group (for example, hydroxymethyl) or a  $C_3$ - $C_8$  cycloalkyl group (such as cyclopentyl or cyclohexyl), or  $R^6$  and  $R^7$  together with the nitrogen atom to which they are attached form a 3 to 8 membered saturated heterocyclic ring (such as pyrrolidinyl or piperidinyl).



R<sup>8</sup> and R<sup>9</sup> each independently represent a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl group such as methyl or ethyl, a C<sub>2</sub>-C<sub>6</sub> hydroxyalkyl group (for example, hydroxymethyl) or a C<sub>3</sub>-C<sub>8</sub> cycloalkyl group (such as cyclopentyl or cyclohexyl), or R<sup>8</sup> and R<sup>9</sup> together with the nitrogen atom to which they are attached form a 3 to 8 membered saturated heterocyclic ring (such as pyrrolidinyl or piperidinyl).

R<sup>10</sup> and R<sup>11</sup> each independently represent hydrogen, a C<sub>1</sub>-C<sub>6</sub> alkyl group such as methyl or ethyl, a C<sub>2</sub>-C<sub>6</sub> hydroxyalkyl group (for example, hydroxymethyl) or a C<sub>3</sub>-C<sub>8</sub> cycloalkyl group (such as cyclopentyl or cyclohexyl), or R<sub>10</sub> and R<sub>11</sub> together with the nitrogen atom to which they are attached form a 3 to 8 membered saturated heterocyclic ring (such as pyrrolidinyl or piperidinyl).

Preferably, ring A is unsubstituted or substituted by one or more substituents, which may be the same or different, selected from C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by at least one substituent selected from halogen or hydroxyl, or C<sub>1</sub>-C<sub>6</sub> alkoxy. Where ring A is substituted, it is preferably substituted by one or two substituents, which may be the same or different.

Preferably n is 1 or 2, especially 1.

X is preferably halogen (such as fluorine, chlorine or bromine) or a C<sub>1</sub>-C<sub>6</sub> alkoxy group such methoxy or ethoxy. Most preferably, X is halogen or a C<sub>1</sub>-C<sub>4</sub> alkoxy group, especially methoxy.

In an embodiment of the invention, m is 1, 2 or 3.

In another embodiment, m is 0.

It will be appreciated that the number and nature of the substituents on rings in the compounds of the invention will be selected so as to avoid sterically undesirable combinations.

- 5 In one preferred group of compounds according to the invention, A is phenyl, pyridyl or quinoliny, optionally substituted by one or more substituents, which may be the same or different, selected from C<sub>1</sub>-C<sub>6</sub> alkoxy or C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by at least one substituent selected from halogen or hydroxyl; B is NHC(O); m is 0; and n is 1

10

Preferred compounds of the invention include:-

2-(2-Adamantyl)-*N*-(5-methoxy-2-methylphenyl)acetamide,

2-(2-Adamantyl)-*N*-1*H*-indol-4-ylacetamide,

- 15 2-(1-Adamantyl)-*N*-quinolin-5-ylacetamide,

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

Where the compounds according to the invention contain one or more asymmetrically substituted carbon atoms, the invention includes all stereoisomers, including enantiomers  
20 and diastereomers, and mixtures including racemic mixtures thereof. Tautomers and mixtures thereof are also included.

Racemates may be separated into individual enantiomers using known procedures (cf. Advanced Organic Chemistry: 3rd Edition: author J March, p104-107). A suitable  
25 procedure involves formation of diastereomeric derivatives by reaction of the racemic material with a chiral auxiliary, followed by separation, for example by chromatography, of the diastereomers and then cleavage of the auxiliary species.


The compounds according to the invention may be provided as pharmaceutically acceptable  
30 salts. Suitable pharmaceutically acceptable salts include base salts such as an alkali metal

salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or amino acids for example lysine. In another aspect, where the compound is sufficiently basic, suitable salts include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid.

Suitable prodrugs of compounds of formula (I) are compounds which are hydrolysed *in vivo* to form compounds of formula (I). These may be prepared by conventional methods.


The present invention further provides a process for the preparation of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt, prodrug or solvate thereof, which comprises:

- (a) when B represents  $\text{NHC(O)}$ , reacting a compound of formula (III)



wherein  $\text{L}^1$  represents a leaving group (e.g. hydroxyl or halogen) and  $n, m$  and  $X$  are as defined in formula (I), with a compound of formula (IV),  $\text{A-NH}_2$ , wherein A is as defined in formula (I); or

- (b) when B represents  $\text{C(O)NH}$ , reacting a compound of formula



wherein X, m and n are as defined in formula (I), with a compound of formula (VI),  
A-C(O)-L<sup>2</sup>, wherein L<sup>2</sup> represents a leaving group (e.g. hydroxyl or halogen) and A is as  
defined in formula (I); and thereafter, if necessary:

5 converting the compound obtained into a further compound according to the invention  
and/or forming a pharmaceutically acceptable salt or prodrug or solvate of the compound.

In processes (a) and (b) the coupling reaction is conveniently carried out in an organic  
solvent such as dichloromethane, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone.

10 If L<sup>1</sup> or L<sup>2</sup> represents a hydroxyl group, it may be necessary or desirable to use a coupling  
agent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP).

Compounds of formulae (III) and (V) are known compounds or may be prepared using  
known techniques by methods analogous to those known in the art. Examples of  
preparation methods for certain of these compounds are given hereinafter in the examples

15

Compounds of formula (I) can be converted into further compounds of formula (I) using  
standard procedures conventional in the art.

20 It will be appreciated that the preparation of compounds of formula (I) may involve, at  
various stages, the addition and removal of one or more protecting groups. The protection  
and deprotection of functional groups is described in 'Protective Groups in Organic  
Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).

25 The compounds of the invention possess activity as P2X<sub>7</sub> receptor antagonists and are  
therefore indicated as pharmaceuticals for use in the treatment of rheumatoid arthritis,  
osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease  
(COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis,  
inflammatory bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and  
metastases of malignant cells, myoblastic leukaemia, diabetes, Alzheimer's disease,  
30 meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke, varicose veins,

sarcoidosis, rhinitis, acute and chronic pain, multiple sclerosis, myeloma, bone loss associated with malignancy and inflammatory and neurodegenerative diseases of the eye such as scleritis, episcleritis, uveitis, Sjogrens syndrome-keratoconjunctivitis, sclerokeratitis, optic neuritis, diabetic retinopathy, retinitis pigmentosa, antimalarial - induced retinopathy.

5 They are also advantageous in the treatment of infectious diseases, e.g. anthrax, in particular inflammatory disease caused or exacerbated by bacterial toxins.

According to a further aspect, therefore, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as defined

10 above for use in therapy of the human or animal body.

The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as defined above, in the manufacture of a medicament for use in therapy.

15 It will be appreciated that "therapy" also includes "prophylaxis" unless otherwise indicated. The terms "therapeutic" and "therapeutically" will be understood accordingly

In a further aspect the present invention provides a method of treating a P2X<sub>7</sub> receptor mediated disease condition which comprises administering to a warm-blooded animal a

20 therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof.

The invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, osteoarthritis, irritable bowel disease, atherosclerosis or psoriasis) which comprises administering a therapeutically effective amount of a compound

25 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient.

The invention also provides a method of treating an obstructive airways disease (e.g. asthma or COPD) which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient.

5

It will be appreciated that dosage administered will vary depending on the compound employed, the mode of administration, the treatment desired and the disorder indicated. Typically, a daily dose of active ingredient in the range of from 0.001 mg/kg to 30 mg/kg body weight is received. This daily dose may be given in divided doses as necessary, the  
10 precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.

The compounds of formula (I) and pharmaceutically acceptable salts, prodrug and solvates  
15 thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more  
20 preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.

The present invention therefore also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof  
25 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions of the invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the  
30 compounds of this invention may be formulated by means known in the art into the form of,

for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

5

In addition to the compounds of the present invention the pharmaceutical composition of the invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to above. Typically unit dosage forms will contain about 1 mg to 500 mg of a

10

Thus, the invention further relates to combination therapies for the treatment of any one of rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, inflammatory bowel diseases, COPD, asthma, allergic rhinitis or cancer or the neurodegenerative diseases such as multiple

15

For the treatment of rheumatoid arthritis, the compounds of the invention may suitably be combined with "biological agents" such as TNF- $\alpha$  inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and Humira) and TNF receptor immunoglobulin

20

Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as

25

naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin. The COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) and the

30

"disease modifying agents" (DMARDs) such as methotrexate, sulphasalazine, cyclosporine A, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or

oral gold.

The present invention also relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist selected from the group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2n cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonists for leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIII 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

The present invention also relates to the combination of a compound of the invention together with an antihistaminic H<sub>1</sub> receptor antagonists including cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

The present invention still further relates to the combination of a compound of the invention together with a gastroprotective H<sub>2</sub> receptor antagonist or the proton pump inhibitors (such as omeprazole)



The present invention still further relates to the combination of a compound of the invention together with an  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine,  
5 naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention  
10 together with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a  $\beta_1$ - to  $\beta_4$ -adrenoceptor agonists including metaproterenol isoproterenol,  
15 isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

The present invention still further relates to the combination of a compound of the invention  
20 together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family.

25 The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, including  
30 prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone

dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B<sub>1</sub> - and B<sub>2</sub> -receptor antagonists; (j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, e.g., allopurinol; (l) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (m) growth hormone secretagogues; (n) transforming growth factor (TGF $\beta$ ); (o) platelet-derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor (GM-CSF); (r) capsaicin cream; (s) Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; and (t) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892 (u) induced nitric oxide synthase inhibitors (iNOS) or (v) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11).

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, induced nitric oxide

synthase inhibitors (iNOS inhibitors), COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) analgesics (such as paracetamol and tramadol), cartilage sparing agents such as diacerein, doxycycline and glucosamine, and intra-articular therapies such as corticosteroids and  
5 hyaluronic acids such as hyalgan and synvisc.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of inflammatory bowel diseases (Ulcerative colitis and Crohn's disease). Suitable agents to be used include sulphasalazine, 5-amino-salicylates, the  
10 thiopurines, azathioprine and 6-mercaptopurine and corticosteroids such as budesonide.

The compounds of the present invention may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and farnesyl transferase inhibitors,  
15 VegF inhibitors, COX-2 inhibitors and antimetabolites such as methotrexate antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine;

The compounds of the invention may also be used in combination with antiviral agents such  
20 as Viracept, AZT, aciclovir and famciclovir, and antisepsis compounds such as Valant.

The compounds of the present invention may also be used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, ACE inhibitors, Angiotensin-2 receptor antagonists and  
25 platelet aggregation inhibitors.

The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, COMT inhibitors  
30 such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine

agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

- 5 The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate;.


The activity and selectivity of the compounds according to the invention may be determined  
10 using an appropriate assay as described, for example in WO 99/29660.

The invention is further illustrated by the following non-limiting examples.

The relevant starting materials are commercially available or may be made by any convenient method as described in the literature or known to the skilled chemist or  
15 described in the Examples herein.

### **Example 1**

#### **2-(2-Adamantyl)-N-(5-methoxy-2-methylphenyl)acetamide**



Thionyl chloride (3.0 mL) and 2-adamantylacetic acid (96 mg) were heated together at 79°C for 5 minutes with stirring before cooled to room temperature and concentrated. The residue was redissolved in dichloromethane (5 mL) and added to a solution of 5-methoxy-2-methylaniline (180 mg) and triethylamine (2.0 mL) in dichloromethane (10 mL). After  
25 stirring for 1 hour, dichloromethane (60 mL) and aqueous hydrochloric acid (40 mL, 2 M)

were added, the layers were separated and the organic fraction was dried, filtered and evaporated. Purification (SiO<sub>2</sub>, dichloromethane) gave the title compound (0.12 g)


<sup>1</sup>H NMR (400 MHz, d<sub>6</sub>-DMSO) δ 9.15 (1H, s), 7.08 (1H, d), 7.05 (1H, d) 6.65 (1H, dd),  
5 3.69 (3H, s), 2.49 (2H, m), 2.21 (1H, m), 2.10 (3H, s), 2.00-1.92 (2H, m), 1.89-1.67 (10H, m), 1.56-1.49 (2H, m).

MS: APCI (+ve) 314 (M+H<sup>+</sup>)

MP: 193-196°C

## 10 **Example 2**

### **2-(2-Adamantyl)-N-1H-indol-4-ylacetamide**



To a solution of 1H-indol-4-amine (20 mg) in dimethylformamide (5 mL) were added 1-(3-  
15 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (29 mg), N,N-dimethylpyridin-4-amine (18.5 mg) and 2-adamantylacetic acid (29 mg) with continuous stirring. The mixture was heated to 60°C for 2 hours under nitrogen. The reaction was subsequently cooled to room temperature and then partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous phase was further extracted with ethyl acetate (2 x 20 mL) and the combined  
20 organics were washed with aqueous potassium hydrogen sulphate (2 x 10 mL, 2 M), saturated aqueous sodium bicarbonate (2 x 10 mL) and brine (20 mL). The organics were then dried, filtered and evaporated under vacuum to give the title compound as a white solid (23 mg).


25 <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.77-7.75 (1H, m), 7.22-7.14 (3H, m), 6.47 (1H, d), 2.60 (2H, d), 2.40 (1H, bt), 1.96-1.86 (4H, m), 1.76 (2H, s), 1.53 (6H, s).

MS: APCI (+ve) 309 (M+H<sup>+</sup>)

MP: 206-208°C

### Example 3

#### **2-(1-Adamantyl)-N-quinolin-5-ylacetamide**



Prepared according to the method of example 2 using 5-quinolinamine.

MS: APCI (+ve) 321 (M+H+).

### Pharmacological Analysis

Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are known to be agonists of the P2X<sub>7</sub> receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p.126). Consequently, when the receptor is activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an increase in the fluorescence of intracellular DNA-bound ethidium bromide is observed. The increase in fluorescence can be used as a measure of P2X<sub>7</sub> receptor activation and therefore to quantify the effect of a compound on the P2X<sub>7</sub> receptor.


In this manner, the title compounds of the Examples were tested for antagonist activity at the P2X<sub>7</sub> receptor. The test was performed in 96-well flat bottomed microtitre plates, the wells being filled with 250 µl of test solution comprising 200 µl of a suspension of THP-1 cells ( $2.5 \times 10^6$  cells/ml) containing  $10^{-4}$ M ethidium bromide, 25 µl of a high potassium buffer solution containing  $10^{-5}$ M bbATP, and 25 µl of the high potassium buffer solution containing  $3 \times 10^{-5}$ M test compound. The plate was covered with a plastics sheet and incubated at 37 °C for one hour. The plate was then read in a Perkin-Elmer fluorescent

plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X<sub>7</sub> receptor agonist) and pyridoxal 5-phosphate (a P2X<sub>7</sub> receptor antagonist) were used separately in the test as controls. From the readings obtained, a pIC<sub>50</sub> figure was calculated for each test compound, this figure being the

5 negative logarithm of the concentration of test compound necessary to reduce the bbATP agonist activity by 50%. Each of the compounds of the Examples demonstrated antagonist activity, having a pIC<sub>50</sub> figure greater than 6.

**Claims**

1. A compound of formula



or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

A represents a phenyl, pyridyl, indolyl, indazolyl, purinyl, pyrimidinyl, thiophenyl, benzothiazolyl, quinolinyl or isoquinolinyl group, each of which may be optionally substituted by one or more substituents, which may be the same or different, selected from  
 10 halogen, amino, nitro, cyano, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by at least one substituent selected from hydroxyl or halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, or a group of formula  
 $-[Y]_p-R^1-R^2$  (II)

where Y represents an oxygen or sulphur atom or a group -N(R<sup>3</sup>)-;

p is 0 or 1;


15 R<sup>1</sup> represents a bond or a C<sub>1</sub>-C<sub>6</sub> alkyl group which may be optionally substituted by at least one substituent selected from hydroxyl, halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyloxy, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, phenyl (optionally substituted by at least one substituent selected from halogen, hydroxyl and C<sub>1</sub>-C<sub>6</sub> alkylsulphonylamino), benzyl, indolyl (optionally substituted by at least one substituent  
 20 selected from C<sub>1</sub>-C<sub>6</sub> alkoxy), oxopyrrolidinyl, phenoxy, benzodioxolyl, phenoxyphenyl, piperidinyl and benzyloxy;

R<sup>2</sup> represents hydrogen, hydroxyl, or a group -NR<sup>4</sup>R<sup>5</sup> except that when R<sup>1</sup> represents a bond, then R<sup>2</sup> represents a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the  
 25 ring system being optionally substituted by at least one substituent selected from hydroxyl,



amino ( $-\text{NH}_2$ ),  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkylamino,  $-\text{NH}(\text{CH}_2)_2\text{OH}$ ,  $-\text{NH}(\text{CH}_2)_3\text{OH}$ ,

$\text{NH}(\text{CH}_2)_4\text{OH}$ ,  $\text{C}_1\text{-C}_6$  hydroxyalkyl, benzyl, and



- $\text{R}^3$  represents a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl group which may be optionally substituted  
 5 by at least one substituent selected from hydroxyl, halogen and  $\text{C}_1\text{-C}_6$  alkoxy;  
 $\text{R}^4$  and  $\text{R}^5$  each independently represent hydrogen, pyrrolidinyl, piperidinyl,  $\text{C}_1\text{-C}_6$   
 alkylcarbonyl,  $\text{C}_2\text{-C}_7$  alkenyl, or  $\text{C}_1\text{-C}_7$  alkyl optionally substituted with at least one  
 substituent selected from carboxyl, hydroxyl, amino ( $-\text{NH}_2$ ),  $\text{C}_1\text{-C}_6$  alkylamino, di- $\text{C}_1\text{-C}_6$   
 alkylamino,  $-\text{NH}(\text{CH}_2)_2\text{OH}$ ,  $\text{C}_1\text{-C}_6$  alkoxy,  $\text{C}_1\text{-C}_6$  alkylthio,  $\text{C}_1\text{-C}_6$  alkoxycarbonyl, and a  
 10 saturated or unsaturated 3- to 10-membered ring system which may comprise at least one  
 ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being  
 optionally substituted by at least one substituent selected from halogen, hydroxyl, oxo,  
 carboxyl, cyano,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  hydroxyalkyl,  $-\text{NR}^6\text{R}^7$ ,  $-(\text{CH}_2)_r\text{NR}^8\text{R}^9$  and  
 $-\text{CONR}^{10}\text{R}^{11}$ ,  
 15 or  $\text{R}^4$  and  $\text{R}^5$  may together with the nitrogen atom to which they are attached form a  
 saturated 4- to 8-membered heterocyclic ring which may comprise a second ring heteroatom  
 selected from nitrogen and oxygen, the ring being optionally substituted by at least one  
 substituent selected from hydroxyl, halogen,  $\text{C}_1\text{-C}_6$  alkyl, and  $\text{C}_1\text{-C}_6$  hydroxyalkyl;  
 $r$  is 1, 2, 3, 4, 5 or 6;  
 20  $\text{R}^6$  and  $\text{R}^7$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  
 $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^6$  and  $\text{R}^7$  together with the nitrogen  
 atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring;  
 $\text{R}^8$  and  $\text{R}^9$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  
 $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^8$  and  $\text{R}^9$  together with the nitrogen atom  
 25 to which they are attached form a 3- to 8-membered saturated heterocyclic ring; and  
 $\text{R}^{10}$  and  $\text{R}^{11}$  each independently represent a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl,  
 $\text{C}_2\text{-C}_6$  hydroxyalkyl or  $\text{C}_3\text{-C}_8$  cycloalkyl group, or  $\text{R}^{10}$  and  $\text{R}^{11}$  together with the nitrogen  
 atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring;

B represents C(O)NH or NHC(O);

n is 1, 2, 3, 4, 5 or 6;

each X is independently selected from halogen or C<sub>1</sub>-C<sub>6</sub> alkoxy; and

m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9;

- 5 with the proviso that when B represents C(O)NH, n is 1 and m is 0, then A is not an unsubstituted phenyl group.

2. A compound according to claim 1 wherein A represents a substituted or unsubstituted group selected from phenyl, pyridyl, indolyl or quinolinyl group.

10

3. A compound according to claim 1 or claim 2 wherein A is substituted by one or more substituents, which may be the same or different, selected from C<sub>1</sub>-C<sub>6</sub> alkoxy or C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by at least one substituent selected from halogen or hydroxyl.

15

4. A compound according to any preceding claim wherein B represents NHC(O).

5. A compound according to any preceding claim wherein m is 1, 2 or 3.

20 6. A compound according to claim 5 wherein X is halogen or C<sub>1</sub>-C<sub>4</sub> alkoxy.

7. A compound according to any of claims 1 to 4 wherein m is 0.

8. A compound according to any preceding claim wherein n is 1 or 2

25

9. A compound of formula (I) according to claim 1 which is selected from  
2-(2-Adamantyl)-N-(1*H*-indol-4-yl)acetamide and  
2-(2-Adamantyl)-N-(5-methoxy-2-methylphenyl)acetamide,  
2-(1-Adamantyl)-N-quinolin-5-ylacetamide,

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

10. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as claimed in any one of claims  
5 1 to 9, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, pro-drug or solvate thereof, as claimed in any one of claims  
10 1 to 9, in combination with one or more additional pharmaceutically active agents.

12. A process for the preparation of a pharmaceutical composition as claimed in claim  
10 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as defined in any one of claims 1 to 9 with a pharmaceutically acceptable adjuvant, diluent or carrier.

15 13. A compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as claimed in any one of claims 1 to 9 for use in therapy


14. Use of a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or  
20 solvate thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of a disease condition mediated by the P2X<sub>7</sub> receptor

15. Use of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament  
25 for use in the treatment of an obstructive airways disease.

16. Use according to claim 14, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.


17. Use of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of osteoarthritis.
- 5 18. Use of a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis.
- 10 19. Use of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof as claimed in any one of claims 1 to 15 in the manufacture of a medicament for use in the treatment of arteriosclerosis.
- 15 20. A method of treating rheumatoid arthritis or osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof as claimed in any one of claims 1 to 9.
- 20 21. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof as claimed in any one of claims 1 to 9.
- 25 22. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, which comprises:
- (a) when B represents  $\text{NHC(O)}$ , reacting a compound of formula (III)

28



wherein  $L^1$  represents a leaving group and  $n, m$  and  $X$  are as defined in formula (I), with a compound of formula (IV),  $A-NH_2$ , wherein  $A$  is as defined in formula (I); or

- 5 (b) when  $B$  represents  $C(O)NH$ , reacting a compound of formula



wherein  $X, m$  and  $n$  are as defined in formula (I), with a compound of formula (VI),  $A-C(O)-L^2$ , wherein  $L^2$  represents a leaving group and  $A$  is as defined in formula (I); and

- 10 optionally thereafter carrying out one or more of the following:  
converting the compound obtained into a further compound according to the invention  
and/or forming a pharmaceutically acceptable salt or prodrug or solvate of the compound.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001154

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 233/26, C07D 209/40, C07D 215/38, A61K 31/167, A61K 31/47,  
A61K 31/404, A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CHEM. ABS DATA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0194338 A1 (ASTRAZENECA AB), 13 December 2001 (13.12.2001) --	1-22
X	WO 0061569 A1 (ASTRAZENECA AB), 19 October 2000 (19.10.2000) --	1-22
X	WO 9929660 A1 (ASTRA AKTIEBOLAG), 17 June 1999 (17.06.1999) -- -----	1-22

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
 "B" earlier application or patent but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 November 2004

Date of mailing of the international search report

25 -11- 2004

Name and mailing address of the ISA/  
 Swedish Patent Office  
 Box 5055, S-102 42 STOCKHOLM  
 Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf/Eö  
 Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE2004/001154

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20-21  
because they relate to subject matter not required to be searched by this Authority, namely:  
See next sheet
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE2004/001154

### Box II.1

Claims 20-21 relate(s) to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001154

WO	0194338	A1	13/12/2001	AU	6447401	A	17/12/2001
				EP	1292590	A	19/03/2003
				GB	0013737	D	00/00/0000
				JP	2004506611	T	04/03/2004
				US	20030187031	A	02/10/2003

---

WO	0061569	A1	19/10/2000	AU	774526	B	01/07/2004
				AU	3994700	A	14/11/2000
				AU	5547000	A	02/01/2001
				BR	0009651	A	08/01/2002
				CA	2368829	A	19/10/2000
				CN	1353702	T	12/06/2002
				CZ	20013608	A	15/05/2002
				EE	200100525	A	16/12/2002
				EP	1171432	A	16/01/2002
				GB	0002330	D	00/00/0000
				HU	0202214	A	28/10/2002
				IL	145505	D	00/00/0000
				JP	2002541249	T	03/12/2002
				NO	20014894	A	10/12/2001
				NZ	514477	A	29/04/2003
				PL	350907	A	10/02/2003
				SK	13422001	A	09/05/2002
				TR	200102911	T	00/00/0000
				US	6492355	B	10/12/2002
				AP	200102041	D	00/00/0000
				AT	250036	T	15/10/2003
				AU	751103	B	08/08/2002
				AU	4950499	A	07/02/2000
				BR	9912109	A	02/05/2001
				CA	2336968	A	27/01/2000
				DE	69911415	D,T	08/07/2004
				DK	1095021	T	24/11/2003
				EE	200100010	A	17/06/2002
				EP	1095021	A,B	02/05/2001
				SE	1095021	T3	
				HK	1035715	A	00/00/0000
				HR	20010039	A	31/12/2001
				HU	0103224	A	28/01/2002
				IL	140346	D	00/00/0000
				JP	2002520395	T	09/07/2002
				NO	20010211	A	15/03/2001
				NZ	508923	A	27/09/2002
				PL	345388	A	17/12/2001
				SE	9901270	D	00/00/0000
				ZA	200108265	A	08/01/2003

---

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001154

WO	9929660	A1	17/06/1999	AT	234274	T	15/03/2003
				AU	746716	B	02/05/2002
				AU	1791499	A	28/06/1999
				BR	9813368	A	03/10/2000
				CA	2312889	A	17/06/1999
				CN	1280560	T	17/01/2001
				DE	69812159	D,T	18/12/2003
				DK	1036058	T	30/06/2003
				EE	200000320	A	15/08/2001
				EP	1036058	A,B	20/09/2000
				SE	1036058	T3	
				ES	2195433	T	01/12/2003
				HK	1028594	A	00/00/0000
				HU	0100431	A	30/07/2001
				IL	136503	D	00/00/0000
				JP	2001525391	T	11/12/2001
				NO	20002785	A	01/08/2000
				NZ	504375	A	29/08/2003
				PL	340890	A	12/03/2001
				PT	1036058	T	31/07/2003
				RU	2197477	C	27/01/2003
				SE	9704545	D	00/00/0000
				SK	8412000	A	07/11/2000
				TR	200001558	T	00/00/0000
				US	6242470	B	05/06/2001

---